San Diego, CA USA (UroToday.com) Multiparametric MRI of the prostate (mpMRI) is a novel technology that improves prostate cancer screening. mpMRI reliably determines lesion location, lesion malignancy, and identifies its aggressiveness. Although the benefits of mpMRI have been recognized in clinical studies, the adoption of mpMRI at institutions is unknown.
Dr. Orberlin and colleagues performed a retrospective study evaluating the implementation of mpMRIs within the US and they presented their findings in this ePoster.
Data was collected retrospectively from October 2013 to December 2015 on patients who underwent mpMRI on a 3.0-T MRI with T1-weighted, triplanar high resolution T2-weighted, dynamic contrast-enhanced MR, and diffusion-weighted imaging. A total of 1,118 mpMRI of the prostate were performed, with the performance number tripling in the final month of data collection.
Their results revealed that 60% of the mpMRI of the prostate performed were for cancer screenings. Of the abnormal screenings, 47% of the patients underwent a prostate biopsy suggesting that the mpMRI may have prevented 261 men from receiving biopsies. Of fusion biopsies, the rate of cancer detection (48%) was found to be significantly greater than the biopsies performed without mpMRI imaging (32%, p=0.03). The authors concluded from their findings that mpMRI of the prostate is continuously increasing in performance rate to aid in the identification and treatment of prostate cancer, and to prevent unnecessary biopsies from being performed.
Presented By: Daniel Oberlin, MD
Written By: Brittany Uribe, BS; Junior Specialist, Department of Urology, University of California, Irvine at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA